These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34993898)

  • 1. Adherence and Persistence with Once-Daily vs Twice-Daily Direct Oral Anticoagulants Among Patients with Atrial Fibrillation: Real-World Analyses from the Netherlands, Italy and Germany.
    Smits E; Andreotti F; Houben E; Crijns HJGM; Haas S; Spentzouris G; Schink T; Gini R; Bartolini C; Penning-van Beest F; Herings R
    Drugs Real World Outcomes; 2022 Jun; 9(2):199-209. PubMed ID: 34993898
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased Risk of Stroke Due to Non-adherence and Non-persistence with Direct Oral Anticoagulants (DOACs): Real-World Analyses Using a Nested Case-Control Study from The Netherlands, Italy and Germany.
    Holthuis E; Smits E; Spentzouris G; Beier D; Enders D; Gini R; Bartolini C; Mazzaglia G; Penning-van Beest F; Herings R
    Drugs Real World Outcomes; 2022 Dec; 9(4):597-607. PubMed ID: 35790603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modeling the impact of real-world adherence to once-daily (QD) versus twice-daily (BID) non-vitamin K antagonist oral anticoagulants on stroke and major bleeding events among non-valvular atrial fibrillation patients.
    McHorney CA; Peterson ED; Ashton V; Laliberté F; Crivera C; Germain G; Sheikh N; Schein J; Lefebvre P
    Curr Med Res Opin; 2019 Apr; 35(4):653-660. PubMed ID: 30265159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once versus twice daily direct oral anticoagulants in patients with recent stroke and atrial fibrillation.
    Polymeris AA; Zietz A; Schaub F; Meya L; Traenka C; Thilemann S; Wagner B; Hert L; Altersberger VL; Seiffge DJ; Lyrer F; Dittrich T; Piot I; Kaufmann J; Barone L; Dahlheim L; Flammer S; Avramiotis NS; Peters N; De Marchis GM; Bonati LH; Gensicke H; Engelter ST; Lyrer PA
    Eur Stroke J; 2022 Sep; 7(3):221-229. PubMed ID: 36082252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice- or once-daily dosing of novel oral anticoagulants for stroke prevention: a fixed-effects meta-analysis with predefined heterogeneity quality criteria.
    Clemens A; Noack H; Brueckmann M; Lip GY
    PLoS One; 2014; 9(6):e99276. PubMed ID: 24911432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Adherence and Persistence with Direct Oral Anticoagulants in Adults with Atrial Fibrillation.
    Manzoor BS; Lee TA; Sharp LK; Walton SM; Galanter WL; Nutescu EA
    Pharmacotherapy; 2017 Oct; 37(10):1221-1230. PubMed ID: 28730619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with Anticoagulation for Atrial Fibrillation: Report from the GLORIA-AF Phase III 1-Year Follow-up.
    Kozieł M; Mazurek M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Brandes A; Paquette M; Zint K; França LR; Lu S; Bartels DB; Huisman MV; Lip GYH
    J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32586056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and predictors of use of warfarin and other common long-term medications in patients with atrial fibrillation.
    Song X; Sander SD; Varker H; Amin A
    Am J Cardiovasc Drugs; 2012 Aug; 12(4):245-53. PubMed ID: 22775446
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to direct oral anticoagulant treatment for atrial fibrillation in the Netherlands: A surveillance study.
    Zielinski GD; van Rein N; Teichert M; Klok FA; Rosendaal FR; van der Meer FJM; Huisman MV; Cannegieter SC; Lijfering WM
    Pharmacoepidemiol Drug Saf; 2021 Aug; 30(8):1027-1036. PubMed ID: 33822401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
    McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
    J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Adherence and Persistence to Direct Oral Anticoagulants in Patients With Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Ozaki AF; Choi AS; Le QT; Ko DT; Han JK; Park SS; Jackevicius CA
    Circ Cardiovasc Qual Outcomes; 2020 Mar; 13(3):e005969. PubMed ID: 32148102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Anticoagulant Prescription Trends, Profile Use, and Determinants of Adherence in Patients with Atrial Fibrillation.
    Perreault S; de Denus S; White-Guay B; Côté R; Schnitzer ME; Dubé MP; Dorais M; Tardif JC
    Pharmacotherapy; 2020 Jan; 40(1):40-54. PubMed ID: 31758592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis.
    Mainbourg S; Cucherat M; Provencher S; Bertoletti L; Nony P; Gueyffier F; Mismetti P; Grange C; Durieu I; Kilo R; Laporte S; Grenet G; Lega JC;
    Thromb Res; 2021 Jan; 197():24-32. PubMed ID: 33161284
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time Trends in Patient Characteristics of New Rivaroxaban Users with Atrial Fibrillation in Germany and the Netherlands.
    Voss A; Smits E; Swart KMA; Balabanova Y; Brobert G; Suzart-Woischnik K; Herings RMC; Schink T; Haug U
    Drugs Real World Outcomes; 2023 Jun; 10(2):215-224. PubMed ID: 36725812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation.
    Beyer-Westendorf J; Ehlken B; Evers T
    Europace; 2016 Aug; 18(8):1150-7. PubMed ID: 26830891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide Versus Exenatide Once Weekly: Persistence, Adherence, and Early Discontinuation.
    Yu M; Xie J; Fernandez Lando L; Kabul S; Swindle RW
    Clin Ther; 2016 Jan; 38(1):149-60. PubMed ID: 26706658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Persistence and adherence to non-vitamin K antagonist oral anticoagulant treatment in patients with atrial fibrillation across five Western European countries.
    Komen JJ; Pottegård A; Mantel-Teeuwisse AK; Forslund T; Hjemdahl P; Wettermark B; Hellfritzsch M; Hallas J; Olesen M; Bennie M; Mueller T; Voss A; Schink T; Haug U; Kollhorst B; Karlstad Ø; Kjerpeseth LJ; Klungel OH
    Europace; 2021 Nov; 23(11):1722-1730. PubMed ID: 34096584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adherence with direct oral anticoagulants in nonvalvular atrial fibrillation new users and associated factors: a French nationwide cohort study.
    Maura G; Pariente A; Alla F; Billionnet C
    Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1367-1377. PubMed ID: 28752560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telemonitoring-based feedback improves adherence to non-vitamin K antagonist oral anticoagulants intake in patients with atrial fibrillation.
    Desteghe L; Vijgen J; Koopman P; Dilling-Boer D; Schurmans J; Dendale P; Heidbuchel H
    Eur Heart J; 2018 Apr; 39(16):1394-1403. PubMed ID: 29300888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.